The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2on the proliferation of colon cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 516-523

  Park, Seok Woo ^a   Kim, Hyo Sun ^a   Choi, Myung Sun ^a   Jeong, Woo Jin ^a   Heo, Dae Seog ^a   Kim, Kwang Hyun ^a,b   Sung, Myung Whun ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; BUCLADESINE; CYCLOOXYGENASE 2; FORSKOLIN; L 161982; L 161983; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N (2 PHENYLCYCLOPENTYL)AZACYCLOTRIDECAN 2 IMINE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INTERACTION; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION;

ADENYLATE CYCLASE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROSTAGLANDIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78751481808     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173278     Document Type: Article

References (30)

1. Abdel-Tawab M, Zettl H, and Schubert-Zsilavecz M (2009) Nonsteroidal anti-inflammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. Curr Med Chem 16:2042-2063.
2. Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, and Powell DW (2004) Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 10:5870-5879. (Pubitemid 39180968)
3. Borer JS (2006) Cyclooxygenase inhibition: what should we do to resolve the confusion? An American perspective. J Cardiovasc Pharmacol 47 (Suppl 1):S87-S91.
4. de Souza Pereira R (2009) Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov 4:157-163.
5. De Wever O, Demetter P, Mareel M, and Bracke M (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123:2229-2238.
6. Fujino H, Xu W, and Regan JW (2003) Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278:12151-12156. (Pubitemid 36800194)
7. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, Sandonato L, D'Alessandro N, Cervello M, and Montalto G (2009) Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann NY Acad Sci 1155:293-299.
8. Grimm M, Gasser M, Bueter M, Strehl J, Wang J, Nichiporuk E, Meyer D, Germer CT, Waaga-Gasser AM, and Thalheimer A (2010) Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Cancer 10:82.
9. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, and Polyak K (2009) Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 106:3372-3377.
10. Jang TJ, Jeon KH, and Jung KH (2009) Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. Yonsei Med J 50:818-824.
11. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, and Vignaud JM (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 140:320-328.
12. Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, and Song YS (2006) Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci 63:930-938.
13. Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Gkermpesi M, Sotiropoulou-Bonikou G, and Papavassiliou AG (2007) EGF-R is expressed and AP-1 and NF-κB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Cell Oncol 29:477-482. (Pubitemid 350136502)
14. Kraus S and Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9:405-410.
15. Kurihara Y, Hatori M, Ando Y, Ito D, Toyoshima T, Tanaka M, and Shintani S (2009) Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis 26:425-432.
16. Lamagna C, Aurrand-Lions M, and Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80:705-713.
17. Lanas A and Ferrandez A (2009) NSAIDs and the colon. Curr Opin Gastroenterol 25:44-49.
18. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, Iuliano F, and Acquaviva AM (2007) PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 293:G673-G681.
19. Li QB, Chen ZC, You Y, and Zou P (2007) Small interfering RNA of cyclooxygenase-2 induces growth inhibition and apoptosis independently of Bcl-2 in human myeloma RPMI8226 cells. Acta Pharmacol Sin 28:1031-1036. (Pubitemid 47020475)
20. Liao D, Luo Y, Markowitz D, Xiang R, and Reisfeld RA (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4:e7965.
21. Ozuysal S, Bilgin T, Ozgur T, Celik N, and Evrensel T (2009) Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival. Eur J Gynaecol Oncol 30:640-645.
22. Pietras K and Ostman A (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316:1324-1331.
23. Roh JL, Sung MW, Park SW, Heo DS, Lee DW, and Kim KH (2004) Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 64:3230-3235.
24. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, and West RB (2010) Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 123:397-404.
25. Sheng H, Shao J, Washington MK, and DuBois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075-18081.
26. Sugimoto Y and Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282:11613-11617.
27. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, et al. (2009) Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 129:1016-1025.
28. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, Gkermpesi M, Varakis I, and Papavassiliou AG (2006) PPAR-γ is expressed and NF-κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132:76-84. (Pubitemid 41752048)
29. Yashiro M, Nakazawa K, Tendo M, Kosaka K, Shinto O, and Hirakawa K (2007) Selective cyclooxygenase-2 inhibitor down-regulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer 120:686-693.
30. Yigit R, Massuger LF, Figdor CG, and Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117:366-372.